Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer

Sher, 2008, Small cell lung cancer, Mayo Clin. Proc., 83, 355, 10.4065/83.3.355 Chan, 2013, Chemotherapy advances in small-cell lung cancer, J. Thorac. Dis., 5, S565 Lattuca-Truc, 2019, Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017, Lung Cancer (Amsterdam, Netherlands), 131, 122, 10.1016/j.lungcan.2019.03.028 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-Cell lung Cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-Cell lung Cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet (London, England, 387, 1540 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-Cell lung Cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet (London, England), 389, 255, 10.1016/S0140-6736(16)32517-X Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet (London, England), 387, 1837, 10.1016/S0140-6736(16)00587-0 Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non-small-Cell lung Cancer, N. Engl. J. Med., 378, 2078, 10.1056/NEJMoa1801005 Paz-Ares, 2018, Pembrolizumab plus chemotherapy for squamous non-small-Cell lung Cancer, N. Engl. J. Med., 379, 2040, 10.1056/NEJMoa1810865 Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N. Engl. J. Med., 378, 2288, 10.1056/NEJMoa1716948 Janjigian, 2018, CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer, J. Clin. Oncol., 36, 2836, 10.1200/JCO.2017.76.6212 Horn, 2018, First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer, N. Engl. J. Med., 379, 2220, 10.1056/NEJMoa1809064 Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N. Engl. J. Med., 375, 1856, 10.1056/NEJMoa1602252 Cheng, 2018, Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy, Oncogenesis, 7, 2, 10.1038/s41389-017-0013-7 Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet (London, England), 390, 2461, 10.1016/S0140-6736(17)31827-5 Hellmann, 2018, Nivolumab plus ipilimumab in lung Cancer with a high tumor mutational burden, N. Engl. J. Med., 378, 2093, 10.1056/NEJMoa1801946 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Saito, 2018, Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer, Mol. Clin. Oncol., 8, 310 Tsuruoka, 2017, PD-L1 expression in neuroendocrine tumors of the lung, Lung Cancer (Amsterdam, Netherlands, 108, 115, 10.1016/j.lungcan.2017.03.006 Yu, 2017, PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung Cancer, J. Thorac. Oncol., 12, 110, 10.1016/j.jtho.2016.09.002 Hirsch, 2017, PD-L1 immunohistochemistry assays for lung Cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project, J. Thorac. Oncol., 12, 208, 10.1016/j.jtho.2016.11.2228 Sakane, 2018, A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma, Oncotarget, 9, 6993, 10.18632/oncotarget.24075 Nguyen, 2018, PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma, Asia. J. Clin. Oncol., 14, 69, 10.1111/ajco.12788 Shimoji, 2016, Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1), Lung Cancer (Amsterdam, Netherlands), 98, 69, 10.1016/j.lungcan.2016.04.021 Lou, 2017, Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma, Open Med. (Warsaw, Poland), 12, 288, 10.1515/med-2017-0042 Chang, 2017, High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers, Oncotarget, 8, 18021, 10.18632/oncotarget.14935 Pan, 2017, Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer, J. Thorac. Dis., 9, 2579, 10.21037/jtd.2017.08.61 Fujimoto, 2018, Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung Cancer, J. Thoracic Oncol., 13, 377, 10.1016/j.jtho.2017.11.123 Miao, 2017, PD-L1 and c-MET expression and survival in patients with small cell lung cancer, Oncotarget, 8, 53978, 10.18632/oncotarget.9765 Heymann, 2017, PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens, Cancer Cytopathol., 125, 896, 10.1002/cncy.21937 Ilie, 2016, Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Ann. Oncol., 27, 147, 10.1093/annonc/mdv489